X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB TORRENT PHARMA UNICHEM LAB/
TORRENT PHARMA
 
P/E (TTM) x -63.1 44.8 - View Chart
P/BV x 0.7 6.3 11.2% View Chart
Dividend Yield % 2.4 0.8 295.9%  

Financials

 UNICHEM LAB   TORRENT PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
TORRENT PHARMA
Mar-18
UNICHEM LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3821,550 24.6%   
Low Rs2341,144 20.5%   
Sales per share (Unadj.) Rs116.3354.7 32.8%  
Earnings per share (Unadj.) Rs-18.940.1 -47.2%  
Cash flow per share (Unadj.) Rs-11.764.2 -18.3%  
Dividends per share (Unadj.) Rs5.0014.00 35.7%  
Dividend yield (eoy) %1.61.0 156.1%  
Book value per share (Unadj.) Rs381.0273.1 139.5%  
Shares outstanding (eoy) m70.34169.22 41.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.63.8 69.8%   
Avg P/E ratio x-16.333.6 -48.4%  
P/CF ratio (eoy) x-26.221.0 -125.1%  
Price / Book Value ratio x0.84.9 16.4%  
Dividend payout %-26.434.9 -75.6%   
Avg Mkt Cap Rs m21,668227,897 9.5%   
No. of employees `0002.314.7 15.5%   
Total wages/salary Rs m2,00611,353 17.7%   
Avg. sales/employee Rs Th3,587.84,083.0 87.9%   
Avg. wages/employee Rs Th880.0772.3 113.9%   
Avg. net profit/employee Rs Th-583.7461.3 -126.5%   
INCOME DATA
Net Sales Rs m8,18060,021 13.6%  
Other income Rs m6102,988 20.4%   
Total revenues Rs m8,79063,009 14.0%   
Gross profit Rs m-1,32013,493 -9.8%  
Depreciation Rs m5054,086 12.4%   
Interest Rs m803,085 2.6%   
Profit before tax Rs m-1,2959,310 -13.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m332,529 1.3%   
Profit after tax Rs m-1,3316,781 -19.6%  
Gross profit margin %-16.122.5 -71.8%  
Effective tax rate %-2.627.2 -9.5%   
Net profit margin %-16.311.3 -144.0%  
BALANCE SHEET DATA
Current assets Rs m23,31852,623 44.3%   
Current liabilities Rs m4,63552,022 8.9%   
Net working cap to sales %228.41.0 22,790.0%  
Current ratio x5.01.0 497.3%  
Inventory Days Days122120 101.8%  
Debtors Days Days12176 159.4%  
Net fixed assets Rs m8,16385,016 9.6%   
Share capital Rs m141846 16.6%   
"Free" reserves Rs m26,66045,376 58.8%   
Net worth Rs m26,80146,222 58.0%   
Long term debt Rs m341,115 0.0%   
Total assets Rs m31,890142,432 22.4%  
Interest coverage x-15.24.0 -377.6%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.30.4 60.9%   
Return on assets %-3.96.9 -56.6%  
Return on equity %-5.014.7 -33.8%  
Return on capital %-4.514.2 -32.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35614,580 29.9%   
Fx outflow Rs m03,600 0.0%   
Net fx Rs m4,35610,980 39.7%   
CASH FLOW
From Operations Rs m-1,1238,942 -12.6%  
From Investments Rs m16,487-47,070 -35.0%  
From Financial Activity Rs m-8,81134,174 -25.8%  
Net Cashflow Rs m6,552-3,655 -179.3%  

Share Holding

Indian Promoters % 50.1 71.5 70.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 7.0 215.1%  
FIIs % 3.0 12.6 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 8.8 360.2%  
Shareholders   20,176 26,511 76.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   FDC LTD.  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note; Banking and Healthcare Stocks Witness Buying Interest(Closing)

Indian share markets ended their session on a positive note today. Gains were largely seen in the banking sector and healthcare sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 25, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS